My friends,Today Tiresias had plans to discuss potential new...

My friends,

Today Tiresias had plans to discuss potential new cancer biomarkers for cancer detection and monitoring for in-vivo endomicroscopy. As you know, Memorial Sloan-Kettering has developed a fluorescent labelled PARP-1 Inhibitor which attaches to pre-cancerous and cancer cells, which, thus far, has been shown to image cancer and precancer in the mouth, the pharynx, the oesophagus, cervix and breast. The potential, however, just for the fluorescent PARP-1, is almost certainly going to be more widely applicable in many other cancers. But that’s just one biomarker. The imaging, of course, is totally dependent on Optiscan.

However, Tiresias is also aware, that at a recent oncology conference, fluorescent PARP-1 inhibitor was the featured headline highlight of the meeting, and has caused a rush up by other cancer researchers, to catch, not only in PARP-1 imaging, which has now put MSK at the forefront in this field, but a rush in every other biomarker, of which there are many, being researched but the hundreds of cancer research labs in the US and around the world. Many other cancer research and clinical laboratories around the world, which has been working on other biomarkers of cancer, are now scrambling to do the same thing for their biomarkers. In the next 6 to 12 months we are going to see many other new cancer fluorescent antibodies against these biomarkers in many other cancers, all of which will need Optiscan confocal endomicroscopy to image. This is a new paradigm and a new era in cancer detection and treatment. Tiresias had planned to discuss this in more detail, but thought better of it as he is not a great typist, tires easily typing, and doesn’t want to overwhelm his friends with too much cancer biology, but instead, he would just like to take a look at the price action, just very briefly.

Tiresias, like of his friends, was very interested in the actions at the AGM. Be assured a new regime is taking serious interest, and previous missteps which have dogged this company are not going to recur. “This time it is different.” So, to the share price action. As Tiresias has mention before, the current capitalization of Optiscan, by comparison the many other biomedical companies listed on the ASX, is ridiculous, being orders of magnitude out. Tiresias understands the history which explains the sentiment which keeps the share price low. The market will catch up though, and soon. There is persistent chatter as to why the share price is not going up; why it's gone down from the peaks at the time of the placement. Well it's pretty simple really. Share price is an index of the psychology of buyers and sellers; balance of fear a greed; of hopes and regrets; of understanding and ignorance. As those, like Tiresias, who have been in the stock for a long time know, OIL spent a long time in a band between 8 and 12 cents. There was a previous placement previously 8 cents, before the share price halved and worse. There were many disappointed and now still stale shareholders who swore to themselves, that the moment they were in the money or near the money they would get out, Tiresias not withstanding. Well they're getting out now and have been getting out. The shares are now being gradually soaked up by fresh strong hungry strong hands from the weak hands. As always, money goes from weak hands to strong hands. Strong hands are patient, and take their time. The weak hands are fearful, impatient, and of course, weak. Why should the strong hands pay any more than they need to. But Tiresias now senses, but of course, though or because he is blind, his senses strong, and sees that the current range trading does not have long to go, and the break, which can only be in one direction, is not far. As the old adage goes, when the last pip squeaks then the share price will move up.

Enjoy, my friends, enjoy.